4th year student in Chemistry
Alzheimer’s disease is a neurodegenerative disorder characterised by the deposition of insoluble aggregates of the peptide amyloid-beta. There is currently no disease-modifying treatment, in part due to an incomplete understanding of how to prevent the aggregates from forming. My work focuses on developing a strategy to systematically develop and optimise small molecules to prevent the aggregation of amyloid-beta. This work has led to the opening of a spin-off biotechnology therapeutics company, and this strategy is going to be generally applied to drug discovery efforts in other protein misfolding diseases, such as Parkinson’s disease, and Type II diabetes.